erythropoiesisstimulating agents esa medications stimulate bone marrow make red blood used treat anemia due end stage kidney disease chemotherapy major surgery certain treatments situations decrease need blood different agents less given common side effects may include joint pain rash vomiting serious side effects may include heart attacks stroke increased cancer growth pure red cell unclear use safe work similar naturally occurring first approved medical use united states world health organizations list essential commercially available agents include epoetin alfa darbepoetin alfa use among athletes prohibited world antidoping esas used maintain hemoglobin lowest level minimizes transfusions best meets persons medical speciality professional organizations recommend use esas people chronic kidney disease ckd hemoglobin levels greater gdl anemia preterm babies esas may help reduce need red blood cell cochrane anaesthesia review group review erythropoietin plus iron versus control treatment including placebo iron preoperative anaemic adults undergoing surgery demonstrated patients much less likely require red cell transfusion transfused volumes unchanged mean difference ci preop hb concentration increased receiving high dose epo low dosecitation needed evidence one agent better another setting esas may fail achieve adequate therapeutic response one following following types esas availablecitation needed recombinant erythropoietin variety glycosylation patterns giving rise alpha beta delta omega forms darbepoetin alfa early literature development often termed novel erythropoiesisstimulating protein nesp form created five substitutions create two new nglycosylation glycoprotein longer terminal halflife meaning possible administer less frequently erythropoiesisstimulating agents history use blood doping agents endurance sports horseracing cycling rowing distance running race walking snowshoeing cross country skiing biathlon mixed martial arts triathlon overall oxygen delivery system blood oxygen levels well heart stroke volume vascularization lung function one major limiting factors muscles ability perform endurance exercise therefore primary reason athletes may use esas improve oxygen delivery muscles directly improves endurance capacity advent recombinant erythropoietin practice autologous homologous blood transfusion partially replaced injecting erythropoietin body naturally produces red cells esas increase hematocrit blood volume red cell mass total red cell mass body providing good advantage sports practice addition ethical considerations sports providing increased red cell mass beyond natural levels reduces blood flow due increased viscosity increases likelihood thrombosis stroke due dangers associated using esas use limited clinic anemic patients boosted back normal hemoglobin levels opposed going normal levels performance advantage leading increased risk deathcitation needed though epo believed widely used certain sports way time directly test test developed scientists french national antidoping laboratory lndd endorsed world antidoping agency wada introduced detect pharmaceutical epo distinguishing nearly identical natural hormone normally present athletes urine first epodoping cases found swiss laboratory doping winter olympic games salt lake city dr catlin founder thendirector ucla olympic analytical lab reported finding darbepoetin alfa form erythropoietin test sample first time summer olympics london alex schwazer gold medalist race walk summer olympics beijing tested positive epo since epo tests performed us sports authorities consisted urine direct test epo tests olympics conducted blood however several compounds identified taken orally stimulate endogenous epo production compounds stabilize hypoxiainducible transcription factors activate epo gene compounds include oxoglutarate competitors also simple ions cobaltii inhalation xenonoxygen mixture activates production transcription factor leads increased production erythropoietin improved performance used purpose russia since least recombinant epo believed come use cycling theory epo use increase significant making useful endurance sports like cycling italian antidoping advocate sandro donati claimed history doping cycling traced italian dr francesco conconi university ferrara conconi worked idea giving athletes transfusions blood donati felt work opened road epo blood doping trial understand role dr michele ferrari former student protege controversial interview mentioning drug team remarkable performance la fl√®che wallonne race ferrari told lequipe journalist jeanmichel rouet epo fundamental effect performance riders used would scandalize journalist pointed several riders suspected dying epo ferrari said epo dangerous abuse dangerous saying also dangerous drink liters orange juice orange juice comment widely ferrari fired shortly continued work industry top riders allegedly including lance year sandro donati working italian national olympic committee presented report accusing conconi linked use epo union cycliste internationale uci instituted new rule riders testing haematocrit immediately disqualified banned racing two robert millar former racer later wrote cycling news limit open invitation dope level pointing normally haematocrit levels would start around drop course grand tour epo staying weeks epo use become widespread festina affair tarnished tour de one manager offered raise christophe bassons would use epo bassons tour de france stuart ogrady one stage held tour de france yellow jersey three days came second points classification assistance floyd landis admitted using performanceenhancing drugs including epo throughout career professional usada released report investigation massive doping us postal service cycling team leadership lance armstrong report contained affidavits numerous riders team including frankie andreu tyler hamilton george hincapie floyd landis levi leipheimer others outlining armstrong used cocktail performanceenhancing substances tour de france notably epo armstrongs seven consecutive tour wins detailed armstrong postal manager johan bruyneel forced team members dope well also went root doping network targeting shadowy doctors back room enablers helped cyclists procure administer drugs well highly placed executives helped avoid doping controls hide positive test results armstrong subsequently stripped victories tour wins performance summer olympics uci concurred decision several doping offenses took place outside normal eightyear statute limitations doping offenses usada contended statute limitations apply due armstrongs fraudulent concealment doping longstanding precedent us law holds statute limitations apply cases fraudulent conduct accordance decision tour organizers removed armstrongs name results races witnesses testified code words used epo included edgar edgar allan poe zumo spanish dynepo brand name form epo developed shire pharmaceuticals first development steps performed hmr aventis aventis obtained license europe company expected launch product europe although patents held american biotechnology company amgen inc may precluded sale united statescitation needed dynepo made cultured human cells therefore expected authentic human form sialic acid oligosaccharide residues hoped would make longeracting product existing brands concerns production would also make dynepo undetectable urine tests epo used time detect doping athletes dynepo withdrawn european markets february commercial july professional cycling team announced thomas dekker tested positive dynepo test taken december dekker riding httpsenwikipediaorgwikierythropoiesisstimulatingagent